Name: Fondaparinux Sodium
Price: 236.00 USD

- Overview
  - Fondaprinux is sulfated pentasaccharide, an ultra low molecular weight synthetic form of heparain with antithrombotic properties. It is analogous to the pentasaccharide sequence in heparin.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Fondaprinux Sodium binds antithrombin and induces a conformational change in antithrombin. It inhibits Factor Xa which is the activated form of the coagulation factor thrombokinase (Stuart-Prower factor). By binding to this site, it accelerates the rate at which antithrombin (ATIII) neutralizes Factor Xa. Neutralization of Factor Xa decreases conversion of prothrombin to thrombin. Disruption of the coagulation cascade prevents thrombin formation.
- Properties
  - Categories
    
    BioActive Small Molecules
    
    CAS Number
    
    114870-03-0
    
    Molecular Formula
    
    C31H43N3O49S8 · 10Na
    
    Molecular Weight
    
    1728.08
    
    Appearance
    
    White to off-white powder
    
    Solubility
    
    Sparingly soluble in water. Insoluble in ethanol.
    
    Other Properties
    
    Source: Synthetic
    Purity Level: ≥95% (anhydrous basis)
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Eukaryotic Cell Culture Applications: In vitro, Fondaparinux Sodium was demonstrated to impair thrombin generation in human platelet-poor plasma in a dose-dependent manner. It also inhibited thrombin formation in platelet-rich plasma. Fondaparinux Sodium did not cross-react in vitro with antibodies present in plasma samples associated with heparain-associated thrombocytopenia (Herbert et al, 1997). Monocytes and monocyte-derived microparticles are cell models that play a procoagulant role in acute coronary syndrome by expressing high tissue factor levels, which then trigger thrombin generation. The in vitro effect of Fondaparinux was compared to Enoxaparin and unfractionated heparin. IC50 values (anti-Xa IU/ml) were 0.59 for activated monocytes and 0.17 for monocyte-derived microparticles (Ben-Hadj-Khalifa et al, 2011).